This study is for people with liver fibrosis and compensated cirrhosis. Liver fibrosis is when scar tissue forms in the liver, and compensated cirrhosis is when the liver is still working well despite damage. The study checks how safe and tolerable the drug AZD2389 is compared to a placebo (a substance with no active drug). It also looks at how the body absorbs and uses AZD2389.

The study lasts about 9 weeks. Participants will have 1 or 2 visits before treatment, 5 clinic visits during 28 days of treatment, and a follow-up visit. Some visits include overnight stays. The study involves around 36 participants divided into two groups, with some receiving AZD2389 and others receiving a placebo.

To join, you must be 18 or older, have liver disease with fibrosis, and not have significant weight changes recently. Some health conditions, like certain heart diseases or infections, may prevent participation.

• The study lasts 9 weeks with multiple visits, including overnight stays.
• A total of 36 participants will be included.
• Participants receive either AZD2389 or a placebo.